Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease: A Systematic Review.

Conclusion: Flares and irAEs in patients with autoimmune disease who are receiving CPIs can often be managed without discontinuing therapy, although some events may be severe and fatal. Prospective longitudinal studies are needed to establish incidence of adverse events and evaluate risk-benefit ratios and patient preferences in this population.
Primary Funding Source: National Institute of Arthritis and Musculoskeletal and Skin Diseases.
PMID: 29297009 [PubMed - as supplied by publisher]

Source: Annals of Internal Medicine - January 2, 2018 Category: Internal Medicine Authors: Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME Tags: Ann Intern Med Source Type: research